MLTX241220C35000
- 0.00
- 0.000.00%
MoonLake Immunotherapeutics Newsroom
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $71
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $73
MoonLake Immunotherapeutics' Promising Phase 3 Trials for PsA Treatment Drives Buy Rating
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $104
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $71
MoonLake Analyst Ratings
Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Advancements and Strong Market Potential
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $62
Barclays Maintains MoonLake Immunotherapeutics(MLTX.US) With Hold Rating, Maintains Target Price $55
MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.
MoonLake Analyst Ratings
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $55 to $100
Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Avidity Biosciences (RNA) and MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics: Strategic Growth and Financial Stability Drive Buy Rating
Wedbush Initiates MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Announces Target Price $73
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100
Wedbush Assumes MoonLake at Outperform, Lowers Price Target of $73
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100